On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This unique rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an RS Rating of over 80 as they begin their biggest climbs.
Looking For Winning Stocks? Try This Simple Routine
Is Supernus Pharmaceuticals Stock A Buy?
Supernus Pharmaceuticals stock is trying to complete a cup without handle with a 34.60 entry. See if it can break out in heavy trade. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company posted negative growth for both the top and bottom lines last quarter.
Supernus Pharmaceuticals stock holds the No. 41 rank among its peers in the Medical-Biomed/Biotech industry group. Pacira Pharmaceuticals, Amphastar Pharmaceutcls and Regeneron Pharmaceutical are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
